Prehospital delay time in acute myocardial infarction: an exploratory study on relation to hospital outcomes and cost.

BACKGROUND Short prehospital delay is associated with improved outcomes in myocardial infarction, but the impact on cost has not been tested. Shortening delay time could reduce health care expenditures. METHODS AND RESULTS Two hundred ninety-eight patients were examined with the use of a historic prospective design at 2 hospital sites. A secondary analysis was performed that used patients with confirmed myocardial infarction from the National Register of Myocardial Infarction and direct and indirect costs from the accounting system at the hospitals. Chi-square, Mann Whitney U, and Fisher exact tests were used for comparisons. Delay and 4 sets of variables were regressed on cost with the significant predictors used to construct a final model. The mean age was 71 +/- 14 years old; 62% were men. There were no major differences in demographics, cardiac history, risk factors, and admission characteristics between short and long delayers. Resource utilization and clinical outcomes were similar between the 2 groups; there was no difference in cost. Additional diagnostic procedures (odds ratio 2.92; 95% confidence interval 1.65-5.15) and complications (odds ratio 3.43; 95% confidence interval 2.03-5.82) were significant predictors of cost. Delay was not a predictor of high cost. CONCLUSIONS Short prehospital delay was not associated with improved clinical outcomes, nor did it predict cost. Explanations include (1) the low utilization of early reperfusion therapy in the short delay group, (2) the study lacked sufficient power to detect a difference in cost between short and long delayers, and (3) the severity of illness could not be adequately measured. This issue warrants further study because of the potential impacts on health care expenditures.

[1]  Richard P. Lewis,et al.  ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction , 1996 .

[2]  M. P. Larsen,et al.  Prehospital delay interval for patients who use emergency medical services: the effect of heart-related medical conditions and demographic variables. , 1993, Annals of emergency medicine.

[3]  H. White,et al.  Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction , 1996, BMJ.

[4]  H. Fineberg,et al.  A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. , 1987, Journal of the American College of Cardiology.

[5]  R. Luepker,et al.  Consequences of a media campaign focusing on delay in acute myocardial infarction. , 1992, American Journal of Cardiology.

[6]  David P Miller,et al.  In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications. , 1995, Circulation.

[7]  F Van de Werf,et al.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. , 1996, Journal of the American College of Cardiology.

[8]  A. Maggioni,et al.  Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. , 1993, Journal of the American College of Cardiology.

[9]  L. Køber,et al.  Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. The TRACE Study Group. Trandolapril Cardiac Evaluation. , 1996, European heart journal.

[10]  S. Schmidt,et al.  The prehospital phase of acute myocardial infarction in the era of thrombolysis. , 1990, The American journal of cardiology.

[11]  A. Jaffe,et al.  Implications for acute intervention related to time of hospital arrival in acute myocardial infarction. , 1986, The American journal of cardiology.

[12]  S. Yusuf,et al.  Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. , 1995, Circulation.

[13]  M. Eisenberg,et al.  Delay between onset of chest pain and seeking medical care: the effect of public education. , 1989, Annals of emergency medicine.

[14]  M. P. Larsen,et al.  'Call fast, Call 911': a direct mail campaign to reduce patient delay in acute myocardial infarction. , 1997, American journal of public health.

[15]  C. Cannon,et al.  One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. , 1995, Journal of the American College of Cardiology.

[16]  E. Braunwald,et al.  Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .

[17]  R. Kleiger,et al.  Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. , 1998, The New England journal of medicine.

[18]  G. Taylor,et al.  Effect of a two-year public education campaign on reducing response time of patients with symptoms of acute myocardial infarction. , 1991, The American journal of cardiology.

[19]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[20]  R. M. Rubison,et al.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. , 1994, Circulation.

[21]  E. Braunwald,et al.  Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB Trial. , 1996, Circulation.

[22]  A. Hasman,et al.  Explaining cost variations in DRGs 'Acute Myocardial Infarction' by severity of illness. , 1994, Health policy.

[23]  R. M. Rubison,et al.  Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction). Participants in the National Registry of Myocardial Infarction. , 1995, The American journal of cardiology.

[24]  P. Kudenchuk,et al.  Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry) , 1996, The American journal of cardiology.

[25]  C. Naylor,et al.  Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[26]  Yuan Zhang,et al.  Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. , 1998, Circulation.

[27]  J. Herlitz,et al.  Prognosis in myocardial infarction in relation to gender. , 1994, American heart journal.

[28]  J. Herlitz,et al.  Delay time between onset of myocardial infarction and start of thrombolysis in relation to prognosis. , 1993, Cardiology.